SOAT1 and autoimmune disease: To date, no medical therapy has proven unequivocal benefit concerning clinical outcomes of PSC (5), but dysregulation in the JAK-STAT pathway is considered an important step in the pathogenesis of several inflammatory and autoimmune diseases with a prominent IL-6, IFN gamma, and IL-17A signature (20).